Meropenem B. Braun

Meropenem, the active ingredient in Meropenem B. Braun, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis, septicemia and febrile neutropenia in hospitalized patients.

GNH USA supplies Meropenem B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections in hospital settings.

Complicated intra‑abdominal infections: provides rapid bacterial eradication in severe abdominal sepsis. Complicated urinary tract infections: clears resistant Gram‑negative pathogens in the urinary tract. Nosocomial pneumonia: treats ventilator‑associated and hospital‑acquired lung infections. Meningitis: penetrates the cerebrospinal fluid to eliminate causative organisms. Septicemia and febrile neutropenia: offers coverage for bloodstream infections in immunocompromised patients.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limited. - Rash: skin erythema or pruritus. - Headache: transient and usually resolves. - Elevated liver enzymes: transient increase in ALT/AST. - Injection site reactions: pain or erythema at the infusion site.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Anaphylaxis: acute allergic reaction with respiratory or cardiovascular compromise. - Seizures: especially in patients with renal impairment or high doses. - Renal toxicity: worsening kidney function in susceptible individuals. - Severe neutropenia: marked reduction in white blood cells. - Hepatic failure: rare but potentially life‑threatening liver injury.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Assess renal function: adjust dose in renal impairment to avoid accumulation. - Monitor for allergic reactions: discontinue if signs of anaphylaxis appear. - Use cautiously in patients with a history of seizures: higher doses may lower seizure threshold. - Adjust in hepatic dysfunction: consider reduced dosing if liver disease is present. - Avoid concomitant valproic acid: carbapenems can reduce valproate levels, risking seizure breakthrough. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several agents; awareness helps prevent reduced efficacy or increased toxicity. Major Interactions (Avoid): - Valproic acid: carbapenems markedly decrease serum valproate concentrations, risking seizure recurrence. - Other carbapenems: concurrent use can lead to antagonistic effects and unnecessary toxicity. - Probenecid: may increase meropenem plasma levels, raising risk of adverse reactions. Moderate Interactions (Monitor Closely): - Loop diuretics: combined nephrotoxic potential requires renal function monitoring. - NSAIDs: may exacerbate renal impairment when used together. - Anticoagulants (warfarin): monitor INR as meropenem can alter coagulation parameters. - Aminoglycosides: increased risk of ototoxicity and nephrotoxicity when co‑administered. - Oral contraceptives: potential reduction in efficacy; advise alternative contraception.